Evidence map›Paper›PMID 24192639›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2014

SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates.

Hironobu Sawada, Naoko Nishimura, Eriko Suzuki, Jie Zhuang, Keiko Hasegawa, Hiroyuki Takamatsu, Kazuo Honda, Keiji Hasumi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Non-human primate models of focal cortical ischemia for neuronal replacement therapy.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Metabolic Profile and Mycoherbicidal Activity of ThreePathogens (Basel, Switzerland) · 2021
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hironobu SawadaDivision of Research and Development, TMS Co., Ltd., Tokyo, Japan.
Naoko NishimuraDivision of Research and Development, TMS Co., Ltd., Tokyo, Japan.
Eriko SuzukiDepartment of Applied Biological Science, Tokyo Noko University, Tokyo, Japan.
Jie ZhuangDepartment of Applied Biological Science, Tokyo Noko University, Tokyo, Japan.
Keiko HasegawaDivision of Research and Development, TMS Co., Ltd., Tokyo, Japan.
Hiroyuki TakamatsuHamamatsu Pharma Research, Hamamatsu, Japan.
Kazuo HondaDepartment of Pharmacology, Showa University, Tokyo, Japan.
Keiji Hasumi1] Division of Research and Development, TMS Co., Ltd., Tokyo, Japan [2] Department of Applied Biological Science, Tokyo Noko University, Tokyo, Japan.
Ryukoku University · JPHamamatsu University · JPShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMTP-7 (Stachybotrys microspora triprenyl phenol-7), a small molecule that promotes plasminogen activation through the modulation of plasminogen conformation, has excellent therapeutic activity against cerebral infarction in several rodent models. Detailed evaluations of SMTP-7 in a primate stroke model are needed for effective, safe drug development. Here we evaluated SMTP-7 in a monkey photochemical-induced thrombotic middle cerebral artery (MCA) occlusion model (n=6), in which MCA occlusion was followed by recanalization/reocclusion. SMTP-7 (10 mg/kg, intravenous infusion) significantly increased the postinfusion MCA recanalization rate (32.5-fold, P=0.043) and ameliorated the post-24-h neurologic deficit (by 29%, P=0.02), cerebral infarct (by 46%, P=0.033), and cerebral hemorrhage (by 51%, P=0.013) compared with the vehicle control animals. In normal monkeys, SMTP-7 did not affect general physiologic or hemostatic variables, including coagulation and platelet parameters. Investigations in rodent models of transient and permanent focal cerebral ischemia, as well as arterial thrombosis and bleeding tests, suggest a role for SMTP-7's regulated profibrinolytic action and neuroprotective properties in the monkey MCA occlusion model. In conclusion, SMTP-7 is effective in treating thrombotic stroke in monkeys. SMTP-7 is thus a promising candidate for the development of alternative therapy for ischemic stroke.

Indexed as

AnimalsCerebral HemorrhageDisease Models, AnimalDose-Response Relationship, DrugDrug Evaluation, PreclinicalFibrinolytic AgentsInfarction, Middle Cerebral ArteryMacaca fascicularisMaleMiceMice, Inbred ICRPhenolsRatsRats, Sprague-DawleyStachybotrysStrokeFibrinolytic AgentsPhenols

Identifiers

PMID24192639
PMCPMC3915202
OpenAlexW2079353155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.